– USA, GA – CIOX Health, the nation’s leader in health information management and record retrieval, announced the appointment of Jeremy Delinsky and Jeff Hammerbacher to its board of directors. Mr. Delinsky is chief technology officer of Wayfair, one of the world’s largest online destinations for home furnishings and décor and Mr. Hammerbacher is the founder and chief scientist at Cloudera and an assistant professor at the Icahn School of Medicine at Mount Sinai.
“CIOX has emerged as the market leader for clinical information exchange and interoperability solutions,” said Matt Holt, chairman of CIOX and managing director of New Mountain Capital. “Jeremy and Jeff bring us experience in the health technology and data science fields that will be critical as we work to enhance our offerings and market presence, capture market share, and meet our short and long term growth objectives.”
Prior to joining Wayfair in July 2015, Mr. Delinsky served as chief product officer as well as chief technology officer at athenahealth. He also served as chairman of the board of directors of the CommonWell Health Alliance, a not-for-profit trade association dedicated to building and creating a vendor-neutral platform that breaks down technological and process barriers to improve health information exchange. In addition, Mr. Delinsky was a member of the Health IT Standards Committee, an appointed body which provides recommendations to the National Coordinator for Health IT, governed by the Secretary of Health and Human Services. He is a Phi Beta Kappa graduate of Wesleyan University and received his MBA from The Wharton School of the University of Pennsylvania.
Mr. Hammerbacher is the founder and chief scientist at Cloudera, a company focused on advancing science by finding innovative and groundbreaking ways to use “big data.” In addition to Cloudera, Mr. Hammerbacher also currently works as a faculty member at the Icahn School of Medicine at Mount Sinai, where he focuses on an initiative to apply data science to medicine. Prior to founding Cloudera in 2008, Mr. Hammerbacher conceived, built, and led the data team at Facebook, where he developed the social media company’s data infrastructure. He also served as entrepreneur-in-residence at Accel Partners and currently serves as a board member for Sage Bionetworks. Mr. Hammerbacher began his career as a quantitative analyst on Wall Street, but quickly moved into the high-tech field and is widely known as one of the top data scientists in the world. He holds a bachelor’s degree in mathematics from Harvard University.
“Jeremy Delinsky and Jeff Hammerbacher are two of the most innovative technology leaders in the industry,” stated Ed Coleman, chief executive officer of CIOX Health. “We look forward to learning from their perspectives and insights as CIOX Health builds more technology-enabled services and solutions to increase the efficiency, speed, quality, and security of health information exchange.”
About CIOX Health
CIOX Health, headquartered in Alpharetta, Georgia, is a health services company that is transforming the way health information is managed. With access across all health information pathways, CIOX Health works as a clinical information intermediary to help all parties excel in the management and exchange of critical health information. With strong relationships and specialized expertise, we deliver the highest level of quality and process optimization to our partners, who include more than 18,000 hospital and provider sites, 100 health plans, and 1 million unique requesters nationwide. Our service offerings include release of information, record retrieval, coding, clinical research, and oncology data services, as well as audit management technology.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
